These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35693049)

  • 1. A case of ceftriaxone-induced liver injury and literature review.
    Guarino M; Perna B; Pastorelli A; Bertolazzi P; Caio G; Maritati M; De Giorgio R; Contini C
    Infez Med; 2022; 30(2):293-297. PubMed ID: 35693049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftriaxone-induced toxic hepatitis.
    Peker E; Cagan E; Dogan M
    World J Gastroenterol; 2009 Jun; 15(21):2669-71. PubMed ID: 19496200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftriaxone-induced hepatotoxicity in patients with common medical infections in Qatar: A retrospective study.
    Barman M; Al Hariri B; Rahman Mustafa A; Ambra N; Amjed I; Eid Nazzal Alharafsheh A; Illahi MN; Hamuda S; Gaafar M; Sharif M
    Qatar Med J; 2022; 2022(3):27. PubMed ID: 35864919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftriaxone-induced cholestatic hepatitis in a child: A case report and a review of the literature.
    Castellazzi ML; Agostoni CV; Palella J; Civeriati D; Marchisio P; Nebbia G
    Front Pediatr; 2022; 10():1051887. PubMed ID: 36545656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholestatic hepatitis with intravenous ceftriaxone.
    Kaur I; Singh J
    Indian J Pharmacol; 2011 Jul; 43(4):474-5. PubMed ID: 21845011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Update on Drug-induced Liver Injury.
    Devarbhavi H
    J Clin Exp Hepatol; 2012 Sep; 2(3):247-59. PubMed ID: 25755441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.
    Bijie H; Kulpradist S; Manalaysay M; Soebandrio A
    J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and fatal cephalosporin-induced autoimmune haemolytic anaemia.
    Boilève A; Gavaud A; Grignano E; Franck N; Carlotti A; Mira JP; Bouscary D; Jozwiak M
    Br J Clin Pharmacol; 2021 Apr; 87(4):2152-2156. PubMed ID: 33075171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute necrotizing calculous cholecystitis after treatment with ceftriaxone in an elderly patient: a case report.
    Shigemori T; Imoto I; Inoue Y; Nishiwaki R; Sugimasa N; Hamaguchi T; Noji M; Takeuchi K; Ito Y; Yasuma T; Gabazza EC; Kato T
    Surg Case Rep; 2022 May; 8(1):97. PubMed ID: 35581487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature.
    Leicht HB; Weinig E; Mayer B; Viebahn J; Geier A; Rau M
    BMC Pharmacol Toxicol; 2018 Oct; 19(1):67. PubMed ID: 30359322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatic tolerance of atypical antipsychotic drugs].
    Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Characterization of Cefazolin-Induced Liver Injury.
    Alqahtani SA; Kleiner DE; Ghabril M; Gu J; Hoofnagle JH; Rockey DC;
    Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1328-1336.e2. PubMed ID: 25528012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature.
    Studentova H; Volakova J; Spisarova M; Zemankova A; Aiglova K; Szotkowski T; Melichar B
    BMC Gastroenterol; 2022 Feb; 22(1):49. PubMed ID: 35123392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carvedilol-Induced Liver Injury, a Rare Cause of Mixed Hepatitis: A Clinical Case.
    Rua J; Prata AR; Marques R; Silva R; Gomes B; Fraga J; Fortuna J
    GE Port J Gastroenterol; 2019 May; 26(3):196-201. PubMed ID: 31192288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin-Induced Liver Injury in Legionnaires' Disease.
    Wong KM; Hosseinnejad K; Palaparty P; Ravakhah K
    Cureus; 2021 Sep; 13(9):e17856. PubMed ID: 34660061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease.
    Bell MJ; Stockwell DC; Luban NL; Shirey RS; Shaak L; Ness PM; Wong EC
    Pediatr Crit Care Med; 2005 May; 6(3):363-6. PubMed ID: 15857541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.
    Lamb HM; Ormrod D; Scott LJ; Figgitt DP
    Drugs; 2002; 62(7):1041-89. PubMed ID: 11985490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci.
    Tapsall JW
    Sex Transm Infect; 2009 Aug; 85(4):256-8. PubMed ID: 19261600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide-associated hepatotoxicity--a case report and literature review.
    Nojkov B; Signori C; Konda A; Fontana RJ
    Anticancer Res; 2012 Sep; 32(9):4117-9. PubMed ID: 22993370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of the third generation cephalosporins.
    Balant L; Dayer P; Auckenthaler R
    Clin Pharmacokinet; 1985; 10(2):101-43. PubMed ID: 3888488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.